Ascendis Pharma A/S (NASDAQ:ASND) Receives “Outperform” Rating from Wedbush

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research note issued to investors on Friday,RTT News reports. They presently have a $181.00 price objective on the biotechnology company’s stock. Wedbush’s target price would suggest a potential upside of 45.64% from the company’s current price.

ASND has been the topic of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a report on Monday, November 4th. Citigroup boosted their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Evercore ISI increased their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. TD Cowen boosted their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, StockNews.com lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $192.54.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $124.28 on Friday. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00. The firm has a fifty day moving average of $132.15 and a 200-day moving average of $132.80. The company has a market cap of $7.54 billion, a price-to-earnings ratio of -13.35 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Analysts predict that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently bought and sold shares of ASND. Signaturefd LLC lifted its position in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of Ascendis Pharma A/S by 61.0% in the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 332 shares during the last quarter. Searle & CO. bought a new stake in Ascendis Pharma A/S in the second quarter worth $205,000. Rhumbline Advisers increased its position in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the last quarter. Finally, Pursue Wealth Partners LLC bought a new position in Ascendis Pharma A/S during the third quarter valued at about $217,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.